S&P 500   3,327.37 (-0.07%)
DOW   29,316.36 (-0.11%)
QQQ   223.60 (+0.10%)
FB   221.43 (-0.32%)
MSFT   167.65 (+0.33%)
AMZN   1,873.19 (+0.45%)
NVDA   248.60 (-0.27%)
BABA   221.56 (-2.58%)
MU   58.57 (+1.58%)
TSLA   540.78 (+5.93%)
AMD   51.15 (+0.43%)
T   38.43 (+0.13%)
F   9.17 (+0.00%)
NFLX   336.90 (-0.82%)
BAC   34.49 (-0.66%)
S&P 500   3,327.37 (-0.07%)
DOW   29,316.36 (-0.11%)
QQQ   223.60 (+0.10%)
FB   221.43 (-0.32%)
MSFT   167.65 (+0.33%)
AMZN   1,873.19 (+0.45%)
NVDA   248.60 (-0.27%)
BABA   221.56 (-2.58%)
MU   58.57 (+1.58%)
TSLA   540.78 (+5.93%)
AMD   51.15 (+0.43%)
T   38.43 (+0.13%)
F   9.17 (+0.00%)
NFLX   336.90 (-0.82%)
BAC   34.49 (-0.66%)
S&P 500   3,327.37 (-0.07%)
DOW   29,316.36 (-0.11%)
QQQ   223.60 (+0.10%)
FB   221.43 (-0.32%)
MSFT   167.65 (+0.33%)
AMZN   1,873.19 (+0.45%)
NVDA   248.60 (-0.27%)
BABA   221.56 (-2.58%)
MU   58.57 (+1.58%)
TSLA   540.78 (+5.93%)
AMD   51.15 (+0.43%)
T   38.43 (+0.13%)
F   9.17 (+0.00%)
NFLX   336.90 (-0.82%)
BAC   34.49 (-0.66%)
S&P 500   3,327.37 (-0.07%)
DOW   29,316.36 (-0.11%)
QQQ   223.60 (+0.10%)
FB   221.43 (-0.32%)
MSFT   167.65 (+0.33%)
AMZN   1,873.19 (+0.45%)
NVDA   248.60 (-0.27%)
BABA   221.56 (-2.58%)
MU   58.57 (+1.58%)
TSLA   540.78 (+5.93%)
AMD   51.15 (+0.43%)
T   38.43 (+0.13%)
F   9.17 (+0.00%)
NFLX   336.90 (-0.82%)
BAC   34.49 (-0.66%)
Log in

NASDAQ:DRNA - Dicerna Pharmaceuticals Stock Price, Forecast & News

$20.33
-1.02 (-4.78 %)
(As of 01/21/2020 12:13 PM ET)
Today's Range
$20.28
Now: $20.33
$21.06
50-Day Range
$20.00
MA: $23.52
$26.92
52-Week Range
$9.39
Now: $20.33
$27.68
Volume28,017 shs
Average Volume580,301 shs
Market Capitalization$1.39 billion
P/E RatioN/A
Dividend YieldN/A
Beta2.4
Dicerna Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the discovery and development of ribonucleic acid interference (RNAi)-based pharmaceuticals. The company develops pharmaceuticals using its GalXC RNAi platform for the treatment of diseases involving the liver, including rare diseases, viral infectious diseases, chronic liver diseases, and cardiovascular diseases. Read More…

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:DRNA
CUSIPN/A
Phone617-621-8097

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$6.18 million
Book Value$3.20 per share

Profitability

Net Income$-88,850,000.00
Net Margins-541.24%

Miscellaneous

Employees78
Market Cap$1.39 billion
Next Earnings Date3/9/2020 (Estimated)
OptionableOptionable

Receive DRNA News and Ratings via Email

Sign-up to receive the latest news and ratings for DRNA and its competitors with MarketBeat's FREE daily newsletter.


Dicerna Pharmaceuticals (NASDAQ:DRNA) Frequently Asked Questions

What is Dicerna Pharmaceuticals' stock symbol?

Dicerna Pharmaceuticals trades on the NASDAQ under the ticker symbol "DRNA."

How were Dicerna Pharmaceuticals' earnings last quarter?

Dicerna Pharmaceuticals Inc (NASDAQ:DRNA) posted its quarterly earnings results on Thursday, November, 7th. The biopharmaceutical company reported ($0.45) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.30) by $0.15. The biopharmaceutical company earned $8.04 million during the quarter, compared to analyst estimates of $11.70 million. Dicerna Pharmaceuticals had a negative return on equity of 58.92% and a negative net margin of 541.24%. View Dicerna Pharmaceuticals' Earnings History.

When is Dicerna Pharmaceuticals' next earnings date?

Dicerna Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Monday, March 9th 2020. View Earnings Estimates for Dicerna Pharmaceuticals.

What price target have analysts set for DRNA?

8 equities research analysts have issued 1 year price objectives for Dicerna Pharmaceuticals' shares. Their forecasts range from $18.00 to $50.00. On average, they expect Dicerna Pharmaceuticals' stock price to reach $31.57 in the next year. This suggests a possible upside of 55.3% from the stock's current price. View Analyst Price Targets for Dicerna Pharmaceuticals.

What is the consensus analysts' recommendation for Dicerna Pharmaceuticals?

8 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Dicerna Pharmaceuticals in the last year. There are currently 8 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Dicerna Pharmaceuticals.

Has Dicerna Pharmaceuticals been receiving favorable news coverage?

News stories about DRNA stock have trended very positive on Tuesday, InfoTrie Sentiment Analysis reports. The research firm identifies negative and positive news coverage by reviewing more than six thousand blog and news sources in real time. The firm ranks coverage of companies on a scale of negative five to five, with scores nearest to five being the most favorable. Dicerna Pharmaceuticals earned a daily sentiment score of 4.0 on InfoTrie's scale. They also gave news coverage about the biopharmaceutical company a news buzz of 0.0 out of 10, meaning that recent news coverage is extremely unlikely to have an impact on the company's share price in the next few days. View News Stories for Dicerna Pharmaceuticals.

Are investors shorting Dicerna Pharmaceuticals?

Dicerna Pharmaceuticals saw a decline in short interest in the month of December. As of December 31st, there was short interest totalling 2,670,000 shares, a decline of 14.1% from the December 15th total of 3,110,000 shares. Based on an average daily volume of 887,700 shares, the days-to-cover ratio is currently 3.0 days. Currently, 4.8% of the shares of the stock are sold short. View Dicerna Pharmaceuticals' Current Options Chain.

Who are some of Dicerna Pharmaceuticals' key competitors?

What other stocks do shareholders of Dicerna Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Dicerna Pharmaceuticals investors own include Axsome Therapeutics (AXSM), Strongbridge Biopharma (SBBP), Arbutus Biopharma (ABUS), Array Biopharma (ARRY), TG Therapeutics (TGTX), Exelixis (EXEL), Sorrento Therapeutics (SRNE), Amarin (AMRN), Arrowhead Pharmaceuticals (ARWR) and Fate Therapeutics (FATE).

Who are Dicerna Pharmaceuticals' key executives?

Dicerna Pharmaceuticals' management team includes the folowing people:
  • Dr. Douglas M. Fambrough III, Co-Founder, CEO, Pres & Director (Age 50)
  • Dr. Bob D. Brown, Chief Scientific Officer & Sr. VP (Age 54)
  • Dr. Ralf H. Rosskamp, Chief Medical Officer (Age 66)
  • Dr. Mark Behlke, Co-Founder & Member of Scientific Advisory Board
  • Prof. John J. Rossi, Co-Founder & Chairman of Scientific Advisory Board (Age 72)

How do I buy shares of Dicerna Pharmaceuticals?

Shares of DRNA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Dicerna Pharmaceuticals' stock price today?

One share of DRNA stock can currently be purchased for approximately $20.33.

How big of a company is Dicerna Pharmaceuticals?

Dicerna Pharmaceuticals has a market capitalization of $1.39 billion and generates $6.18 million in revenue each year. The biopharmaceutical company earns $-88,850,000.00 in net income (profit) each year or ($1.20) on an earnings per share basis. Dicerna Pharmaceuticals employs 78 workers across the globe.View Additional Information About Dicerna Pharmaceuticals.

What is Dicerna Pharmaceuticals' official website?

The official website for Dicerna Pharmaceuticals is http://www.dicerna.com/.

How can I contact Dicerna Pharmaceuticals?

Dicerna Pharmaceuticals' mailing address is 87 CAMBRIDGEPARK DRIVE, CAMBRIDGE MA, 02140. The biopharmaceutical company can be reached via phone at 617-621-8097 or via email at [email protected]


MarketBeat Community Rating for Dicerna Pharmaceuticals (NASDAQ DRNA)

Community Ranking:  2.9 out of 5 (star star)
Outperform Votes:  364 (Vote Outperform)
Underperform Votes:  260 (Vote Underperform)
Total Votes:  624
MarketBeat's community ratings are surveys of what our community members think about Dicerna Pharmaceuticals and other stocks. Vote "Outperform" if you believe DRNA will outperform the S&P 500 over the long term. Vote "Underperform" if you believe DRNA will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 1/21/2020 by MarketBeat.com Staff

Featured Article: Current Ratio

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel